RankingsPricing
  1. US-listed companies
  2. SANGAMO THERAPEUTICS, INC

SANGAMO THERAPEUTICS, INCSGMO

Market cap
$139.73M
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023
Net loss--------69-95-121-178-192-258
Depreciation and amortization111111124691215
Goodwill and Intangible Asset Impairment------------89
(Accretion of discount) amortization of premium on marketable securities----1-1-01651-312
Impairment of long-lived assets------------66
Amortization and other changes in operating lease right-of-use assets---------6-8-8-8-
Depreciation and amortization111111124691215
Stock-based compensation856912159151926333227
(Accretion of discount) amortization of premium on marketable securities----1-1-01651-312
Gain on free shares--------000--
Amortization in operating lease right-of-use assets------------7
Net (gain) loss on disposal of property and equipment--0-----0--0-00--
Deferred income tax benefit-----6-0-------6
Adjustment of CIRM award liability related to termination of the grant----------6--
Stock-based compensation856912159151926333227
Other------0-0------1
Adjustment of CIRM award liability related to termination of the grant----------6--
Interest receivable-0-000-0-00000-10-0
Accounts receivable13-17-82-2132-321-2-3
Prepaid expenses and other assets0-000-011371075-6
Accounts payable and other accrued liabilities---4-1-23-6-411-8136
Accrued compensation and employee benefits011-0-00334701-13
Deferred revenues-------99-36217-84-91-161
Lease liabilities------------2-
Lease liabilities-------------5
Other non-current liabilities-------2411-0-0
Net cash used in by operating activities-26-8-19----37-144170-233-224-225
Purchases of marketable securities1139111922825821925245144457133827760
Maturities of marketable securities---128338237179392405315603355-
Maturities of marketable securities------------215
Sales of marketable securities8310351-------7220
Purchases of property and equipment1101214432115232021
Purchase of additional Sangamo France shares--------010--
Net cash provided by investing activities-2011-68-----178-60-27224859154
At-The-Market Offering----------278515
Employee Stock----------321
Employee Stock----------321
Proceeds from issuance of common stock52291371171622---
Taxes paid related to net share settlement of equity awards--25211001322
Proceeds from exercise of stock options--------4960-
Net cash provided by financing activities52276----232142153338515
Effect of exchange rate changes on cash and cash equivalents, and restricted cash--------0-0-011
Net (decrease) increase in cash, cash equivalents, and restricted cash-------91-625148-78-55
Capital Expenditures Incurred but Not yet Paid-----4----270
Buy-out of non-controlling interest----------1--
Right-of-use assets obtained in exchange for lease obligations--------31110--